- Home
- IMTXW
IMTXW
Immatics N.V.
as 07-26-2024 4:00pm EST
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
| Founded: | N/A | Country: | Germany |
| Employees: | 343 | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | N/A |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | N/A | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Immatics N.V. News
IMTXW Breaking Stock News: Dive into IMTXW Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Investors in Immatics (NASDAQ:IMTX) have seen returns of 24% over the past five years
GlobeNewswire
9 days ago
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
Simply Wall St.
a month ago
Here's Why Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Is The Least Of Shareholders' Concerns
Simply Wall St.
2 months ago
Here's Why We're Not Too Worried About Immatics' (NASDAQ:IMTX) Cash Burn Situation
GlobeNewswire
2 months ago
Immatics Announces First Quarter 2024 Financial Results and Business Update
GlobeNewswire
4 months ago
Immatics Announces Full Year 2023 Financial Results and Corporate Update
Simply Wall St.
4 months ago
With 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big guns
Reuters
6 months ago
UPDATE 1-Brazil's military reinforces border with Venezuela and Guyana due to Esequibo
Compare IMTXW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMTXW Immatics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.